NAD injection dosage: protocol guide

Key takeaways

• NAD injection doses typically range from 100-500 mg per subcutaneous injection
• Most protocols start at 50-100 mg to assess tolerance before increasing
• Loading phases use 2-3 injections per week for 4-8 weeks; maintenance drops to 1-2 per week
• Subcutaneous injection is the preferred route for self-administration; intramuscular is an alternative
• Dosing is individualized based on age, health status, goals, and tolerance
• Higher doses produce more side effects without proportionally better outcomes

Understanding NAD injection dosing is straightforward once you know the basic framework. This guide covers the typical protocols, how providers adjust them, and the practical details of administration.

This is not medical advice. A licensed provider should determine your specific dose and protocol based on your health history.

Typical dosage ranges

NAD injection protocols follow a dose-escalation approach. You start low and increase as tolerance is confirmed.

Starting dose: 50-100 mg subcutaneously. This initial dose is primarily a tolerance test. Most patients experience minimal side effects at this level, which makes it a safe baseline.

Standard dose: 100-250 mg per injection. This is where most maintenance protocols land. A 2023 multicenter trial of oral NMN (an NAD+ precursor) found that doses of 300-600 mg/day raised blood NAD+ levels most efficiently, suggesting similar ranges are relevant for direct NAD+ administration [1].

Higher dose: 250-500 mg per injection. Used in some intensive protocols, particularly during loading phases or for patients with documented low NAD+ levels. Side effects (nausea, flushing, cramping) become more common above 250 mg [2].

Maximum dose: Most providers cap subcutaneous injections at 500 mg. Above this threshold, side effect frequency increases substantially without clear evidence of proportionally better results. By comparison, IV NAD+ drips commonly deliver 250-1,000 mg per session, but over 2-4 hours through continuous infusion rather than as a single bolus.

Loading vs maintenance protocols

Most NAD injection programs use a two-phase approach.

Loading phase

The loading phase aims to rapidly restore NAD+ levels from a depleted baseline. Typical parameters:

• 200-500 mg per injection
• 2-3 injections per week
• Duration: 4-8 weeks

The rationale is that decades of NAD+ decline cannot be reversed with occasional dosing. A loading phase saturates tissues and allows the NAD+-dependent enzyme systems (sirtuins, PARPs) to fully activate. Think of it like filling a pool versus keeping it topped off.

How quickly blood NAD+ levels respond to supplementation varies by individual. A 2024 study of personalized NMN dosing found that baseline NAD+ concentration predicted how much supplementation was needed to reach target levels [3]. Patients starting with lower baselines needed higher or longer loading doses.

Maintenance phase

Once the loading phase is complete, the goal shifts to maintaining elevated NAD+ levels with less frequent dosing:

• 100-250 mg per injection
• 1-2 injections per week
• Duration: ongoing

Some patients cycle maintenance protocols (e.g., 3 months on, 1 month off), though there is no published evidence to support cycling over continuous use. Others use maintenance indefinitely as part of a broader longevity protocol.

Example protocol

Phase	Dose	Frequency	Duration
Week 1	100 mg	3x/week	Tolerance assessment
Weeks 2-4	200 mg	3x/week	Loading
Weeks 5-8	250 mg	2-3x/week	Loading (continued)
Week 9+	150-200 mg	1-2x/week	Maintenance

This is representative, not prescriptive. Your provider may modify any parameter based on your response.

Subcutaneous vs intramuscular injection

Two routes are used for NAD+ injections. Subcutaneous is more common.

Subcutaneous (SubQ)

Injected into the fat layer just under the skin. Common sites include the abdomen (2 inches from the navel), front of the thigh, and back of the upper arm.

Advantages: Easier to self-administer. Less painful. Creates a depot effect that releases NAD+ gradually. Requires shorter needles (typically 27-30 gauge, 0.5 inch).

Absorption: Slower peak but more sustained release compared to intramuscular. NAD+ enters local capillaries over several hours.

This is the same technique used for most peptide injections. If you are familiar with subcutaneous administration from other therapies, NAD+ follows the same process.

Intramuscular (IM)

Injected into muscle tissue, typically the deltoid (upper arm) or vastus lateralis (outer thigh).

Advantages: Faster absorption than SubQ due to higher blood flow in muscle tissue. May be preferred when a quicker onset is desired.

Disadvantages: More painful. Requires longer needles (23-25 gauge, 1-1.5 inch). Harder to self-administer in some sites. Higher risk of injection site soreness.

Most at-home NAD injection protocols use the subcutaneous route. IM is sometimes used in clinical settings.

How to administer an NAD injection

For patients cleared for self-administration, the process mirrors standard subcutaneous peptide injection:

1. Wash hands thoroughly and gather supplies: NAD+ vial, alcohol swabs, insulin syringe
2. Clean the vial top with an alcohol swab
3. Draw the prescribed dose into the syringe, removing air bubbles
4. Select an injection site (abdomen, thigh, or upper arm) and clean with alcohol
5. Pinch the skin to create a fold of subcutaneous tissue
6. Insert the needle at a 45-degree angle
7. Inject slowly over 5-10 seconds (slower injection reduces stinging)
8. Remove the needle and apply gentle pressure with a cotton ball
9. Dispose of the syringe in a sharps container

Rotate injection sites between sessions. Do not inject into the same spot consecutively. For detailed technique, see our guide on how to inject peptides and the peptide dosage calculator for volume calculations.

Factors that affect dosing

Your provider considers several factors when determining the right dose:

Age. NAD+ decline accelerates after 40. Older adults with more pronounced depletion may benefit from higher loading doses. A 2021 review documented the trajectory of age-related NAD+ decline and its metabolic consequences [4].

Body weight. Larger individuals may need proportionally higher doses, though weight-based dosing for NAD+ has not been formally established in clinical trials.

Baseline NAD+ levels. Some providers test blood NAD+ levels before starting therapy. A 2024 study proposed personalized NMN dosing based on baseline NAD+ concentration, finding significant variability between individuals [3].

Goals. Anti-aging maintenance may require a different protocol than recovery from chronic fatigue or post-addiction support. The treatment goal shapes both dose and duration.

Tolerance. Some patients are sensitive to NAD+ and experience side effects at standard doses. These individuals benefit from a slower titration. See our NAD injection side effects guide for what to expect.

Other therapies. Patients combining NAD+ with other peptide protocols may need adjusted timing to avoid overlapping side effects. Common combinations include NAD+ with sermorelin or CJC-1295/Ipamorelin.

NAD injection concentration and volume

NAD+ injectable solutions come in different concentrations, which affects injection volume:

• 100 mg/mL concentration: A 200 mg dose requires 2 mL of fluid
• 200 mg/mL concentration: A 200 mg dose requires only 1 mL
• 500 mg/mL concentration: A 200 mg dose requires 0.4 mL

Higher concentrations mean smaller injection volumes, which is more comfortable and reduces injection site reactions. However, more concentrated solutions may cause more localized stinging.

Most compounding pharmacies supply NAD+ at 100-200 mg/mL. The prescription should specify both the concentration and the volume per dose. If you are sourcing through a compounding pharmacy, confirm the concentration before calculating your injection volume.

Storage and handling

NAD+ injectable solution requires proper storage to maintain potency:

• Refrigerate at 36-46°F (2-8°C) when not in use
• Protect from light (store in original box or wrap vial in foil)
• Do not freeze
• Note the expiration date on the vial
• Discard if the solution changes color, becomes cloudy, or contains particles
• Use bacteriostatic water only if reconstituting from powder (most NAD+ arrives as pre-mixed solution)

Multi-dose vials, once punctured, are typically good for 28 days when refrigerated. Follow your pharmacy’s specific guidance.

Frequently asked questions

What is the best NAD injection dose for beginners?▼

Start with 50-100 mg subcutaneously. This allows you to assess tolerance with minimal risk of side effects. Most patients can increase to 200 mg within the first week if the initial dose is well-tolerated.

How often should I get NAD injections?▼

During a loading phase, 2-3 times per week is standard. For maintenance, 1-2 times per week is typical. Some patients eventually move to weekly or even twice-monthly injections. Your provider determines frequency based on your response.

Can I take too much NAD+?▼

Excessive doses increase side effects (nausea, flushing, cramping) without clear evidence of better outcomes. There is a ceiling effect where additional NAD+ no longer proportionally increases tissue levels. Most providers keep subcutaneous doses at or below 500 mg per injection.

Should I inject NAD+ in the morning or evening?▼

Most providers recommend morning or early afternoon injection. NAD+ supports cellular energy production, and some patients report increased alertness or difficulty sleeping if they inject late in the day. That said, individual responses vary.

How long does an NAD injection protocol last?▼

Loading phases typically run 4-8 weeks. Many patients then continue maintenance indefinitely. Some cycle between active periods and breaks. There is no established endpoint because the underlying NAD+ decline is ongoing.

Do I need blood work before starting NAD injections?▼

Some providers order baseline blood NAD+ levels, though this test is not universally available or standardized. At minimum, a basic metabolic panel and liver function tests are reasonable before starting. Learn more about the process through our peptide therapy consultation guide.

References

1. Yi L, Maier AB, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. PubMed
2. Song Q, Zhou X, et al. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023;14(6):1416-1435. PubMed
3. Kuerec AH, Wang W, et al. Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration. Mech Ageing Dev. 2024;218:111918. PubMed
4. Covarrubias AJ, Perrone R, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PubMed